Winhycare Pharma · EU, EEA, UK & Switzerland
Peptide and biosimilar lyophilisation for European companies
Lyophilisation (freeze-drying) and vial filling of peptides and biosimilars for research peptide brands, biotech and pharmaceutical companies in all 32 countries of the EU, EEA, the United Kingdom and Switzerland, processed at WHO-GMP certified manufacturing partners in India.
By Kareem Ahmed Basha, Director & Chief Scientific Officer · Reviewed by Nisar Mohammed · Updated
WHO-GMPCertified manufacturing partners
- Pharmazeutische Lyophilisierung (Gefriertrocknung) und Abfüllung von Peptiden in VialsDeutsch
- Lyophilisation pharmaceutique et remplissage de flacons de peptidesFrançais
- Liofilizzazione farmaceutica e riempimento di flaconi per peptidiItaliano
- Liofilización farmacéutica y llenado de viales de péptidosEspañol
- Farmaceutische lyofilisatie (vriesdrogen) en afvullen van peptiden in flaconsNederlands
- Liofilizacja farmaceutyczna peptydów i napełnianie fiolekPolski
In short
- We lyophilise and fill peptides and biosimilars into vials, from cycle development through engineering, pilot and commercial batches.
- Projects are managed from Hyderabad, India, and processed at WHO-GMP certified manufacturing partners in India, with India-based processing costs.
- Bring your own peptide or biosimilar: lyophilisation and vial filling are offered on their own for material you supply.
- Research-use-only material carries the RUO designation; commercial work on approved products is subject to approvals, licences and site authorisations.
- WHO-GMP certification is not an EU GMP certificate. For EU clinical or commercial supply, the site must meet EU GMP requirements and be named in the application, and each imported batch of an authorised medicine is tested in the EU and certified by a Qualified Person, as there is no EU and India mutual recognition agreement.
The service in under two minutes
Read the transcript
Many peptides and biosimilars are unstable in solution. Lyophilisation solves that. The product is filled into vials and frozen. Under vacuum, the ice turns straight to vapour. Then the remaining bound water is removed. What's left is a stable, dry cake, sealed in the vial and ready to reconstitute. Winhycare Pharma lyophilises and fills peptides and biosimilars into vials, at WHO-GMP certified manufacturing partners in India. We develop the freeze-drying cycle for your formulation. We control freezing and drying, optimise residual moisture and reconstitution, and handle nitrogen flushing, stoppering, crimp sealing and documentation. Already have your peptide? Send it to us, and we'll lyophilise it as a standalone service. Or source the peptide and the lyophilisation together, in one project. Every project starts with a technical scope and cycle development, then moves through engineering and pilot batches, to commercial campaigns for approved products. Research-use-only material carries the right designation, and commercial work follows the applicable approvals. We work with companies across Europe, the United Kingdom and the United States. For a proposal, send us your product details, intended use, quantity per vial, batch size, testing needs and timeline. Winhycare Pharma. Peptide and biosimilar lyophilisation, from cycle to vial.
Who in Europe uses the service
Research peptide brands and distributors
Lyophilisation and vial filling of research peptides, handled with the appropriate Research Use Only (RUO) designation.
Biotech companies
Development work from formulation and cycle development to engineering and pilot batches.
Pharmaceutical companies
Commercial manufacturing of approved products, subject to regulatory approvals, manufacturing licences and site authorisations.
Universities and research institutes
Lyophilised research material for laboratory studies, supplied for research use only.
EU requirements depend on the end use
The same lyophilisation step sits under different rules depending on whether the vials are for laboratory research, a clinical trial or an authorised medicine.
Research use only (RUO)
RUO material is not a medicinal product. It is processed and labelled with the RUO designation and is not for human or veterinary use. Buyers are responsible for national import and use rules.
Clinical trials
Investigational medicinal products must be made under GMP for investigational medicinal products (Delegated Regulation (EU) 2017/1569) and released by a Qualified Person under the Clinical Trials Regulation (EU) No 536/2014.
Authorised medicines
Batches made outside the EU must be tested in the EU and certified by a Qualified Person before release (Article 51 of Directive 2001/83/EC), unless a mutual recognition agreement applies; there is none between the EU and India. The importer needs a manufacturing and import authorisation.
Sterile manufacturing
Lyophilised injectable products fall under EU GMP Part I and Annex 1 (manufacture of sterile medicinal products), which applies to the filling and freeze-drying steps.
United Kingdom and Switzerland: Great Britain applies its own import and QP certification rules through the MHRA, and Switzerland through Swissmedic. We confirm the documentation each project needs with your regulatory team.
Countries we serve and their medicines regulators
All EU member states, the EEA countries (Iceland, Liechtenstein, Norway), the United Kingdom and Switzerland. The authority listed is the national competent authority for medicines, which you will deal with for authorisations and inspections in that country.
| Country | Medicines regulator | Service page |
|---|---|---|
| Austria | BASG (Federal Office for Safety in Health Care) | Deutsch |
| Belgium | FAMHP (Federal Agency for Medicines and Health Products) | Français |
| Bulgaria | BDA (Bulgarian Drug Agency) | English |
| Croatia | HALMED (Agency for Medicinal Products and Medical Devices) | English |
| Cyprus | Pharmaceutical Services, Ministry of Health | English |
| Czechia | SÚKL (State Institute for Drug Control) | English |
| Denmark | Danish Medicines Agency | English |
| Estonia | State Agency of Medicines | English |
| Finland | Fimea (Finnish Medicines Agency) | English |
| France | ANSM (French National Agency for Medicines and Health Products Safety) | Français |
| Germany | BfArM and Paul-Ehrlich-Institut; GMP inspections by the federal states | Deutsch |
| Greece | EOF (National Organisation for Medicines) | English |
| Hungary | NNGYK (National Center for Public Health and Pharmacy) | English |
| Iceland | Icelandic Medicines Agency | English |
| Ireland | HPRA (Health Products Regulatory Authority) | English |
| Italy | AIFA (Italian Medicines Agency) | Italiano |
| Latvia | State Agency of Medicines | English |
| Liechtenstein | Office of Public Health | Deutsch |
| Lithuania | State Medicines Control Agency | English |
| Luxembourg | Division of Pharmacy and Medicines, Ministry of Health | Français |
| Malta | Malta Medicines Authority | English |
| Netherlands | CBG-MEB (Medicines Evaluation Board); GMP inspections by IGJ | Nederlands |
| Norway | Norwegian Medical Products Agency | English |
| Poland | URPL (Office for Registration of Medicinal Products); GMP inspections by GIF | Polski |
| Portugal | INFARMED | English |
| Romania | ANMDMR (National Agency for Medicines and Medical Devices) | English |
| Slovakia | ŠÚKL (State Institute for Drug Control) | English |
| Slovenia | JAZMP (Agency for Medicinal Products and Medical Devices) | English |
| Spain | AEMPS (Spanish Agency of Medicines and Medical Devices) | Español |
| Sweden | Swedish Medical Products Agency | English |
| Switzerland | Swissmedic | Deutsch |
| United Kingdom | MHRA (Medicines and Healthcare products Regulatory Agency) | English |
How a European project runs
- 1Project discussion and technical scope
- 2Formulation and cycle development
- 3Engineering batch
- 4Pilot processing
- 5Commercial campaign (approved products)
Most projects begin with engineering or pilot batches. Lyophilised vials are shipped from India to Europe; the temperature range, packaging and shipping documents are agreed for each project.
Biosimilars and other biologics
Alongside peptides, we lyophilise and fill biosimilars into vials at our WHO-GMP certified manufacturing partners. Protein formulations need a cycle built around lyoprotectants, collapse temperature, residual moisture and aggregation.
Biosimilar and protein lyophilisation →Frequently asked questions
Do you work with companies in every European country?
Yes. We work with companies in all EU and EEA countries, the United Kingdom and Switzerland. Projects are run in English, and the service page is also available in German, French, Italian, Spanish, Dutch and Polish.
Where is the lyophilisation carried out?
Projects are managed by Winhycare Pharma in Hyderabad, India, and processed at WHO-GMP certified manufacturing partners in India.
Can we send our own peptide just for lyophilisation?
Yes. Lyophilisation and vial filling are offered as a standalone service for peptides or biosimilars you supply. You do not need to buy the peptide from us.
Can lyophilised vials be supplied for clinical trials in the EU?
Clinical-trial material must be made under GMP for investigational medicinal products and released by a Qualified Person in the EU. Whether a given project can meet those requirements is assessed with you during the technical scope.
What happens when an approved medicine made in India is imported into the EU?
Each batch is tested in the EU and certified by a Qualified Person before release (Article 51 of Directive 2001/83/EC), because there is no mutual recognition agreement between the EU and India. Commercial projects are assessed one by one against these requirements and the applicable approvals and licences.
Do you lyophilise biosimilars as well as peptides?
Yes. We lyophilise and fill peptides and biosimilars into vials through our manufacturing partner. Commercial processing of approved products is subject to the applicable regulatory approvals, manufacturing licences and site authorisations.
Can research-use-only peptides be lyophilised for European distributors?
Yes. Research peptides are lyophilised and filled with the appropriate RUO designation. They are not for human or veterinary use, and distributors remain responsible for the rules in the countries where they sell.
Sources
- Directive 2001/83/EC (Article 51), EUR-Lex
- Regulation (EU) No 536/2014 on clinical trials, EUR-Lex
- Delegated Regulation (EU) 2017/1569, GMP for investigational medicinal products, EUR-Lex
- EudraLex Volume 4, EU GMP guidelines (Part I and Annex 1), European Commission
- Mutual recognition agreements (MRA), European Medicines Agency
Discuss a lyophilisation project in Europe
Share the product, specifications and regulatory status, intended use, quantity per vial and formulation, batch size and vial configuration, testing and documentation needs, and your target market and timeline. Contact Kareem Ahmed Basha ([email protected]) or [email protected].
More from Winhycare Pharma · Peptide APIs
Products & services
- Peptide APIs & CMO services
- Peptide API supplier (5 APIs)
- Semaglutide API supplier
- Tirzepatide API supplier
- Research peptides (RUO), >99% purity
- GLP-1 research peptides
- Custom peptide synthesis
- Peptide lyophilisation (lyophilization) services
- Biosimilar and protein lyophilisation
- Lyophilisation for European companies
- Peptide CDMO & contract manufacturing
- Peptide API supplier for Europe
- Peptide API supplier for the USA
Guides
Peptide Research Library →- Amycretin: what it is, how it works and what studies have found
- Amylin analogues explained: amylin receptors and the peptides that target them
- AOD-9604: what it is, how it works and what studies have found
Aseptic fill finish explained: how sterile peptide vials are filled, closed and released
- BPC-157: what it is, how it is thought to work and what studies have found
- BPC-157 vs TB-500: how the two peptides differ in structure, evidence and regulatory status
- Cagrilintide: what it is, how it works and what studies have found
- CJC-1295: what it is, how it works and what studies have found
- What is a drug master file? DMF, ASMF and CEP for a peptide API, with the CTD Module 3 sections
- Eloralintide: what it is, how it works and what studies have found
- Endotoxin testing for peptides: LAL, recombinant factor C, limits and interference
What is EU GMP Annex 1? The 2022 sterile manufacturing rules explained, clause by clause
- FDA-approved peptide drugs: a list by INN, approval year, target and length
- GLP-1 receptor agonists explained: how they work, the full list, and where research is heading
- GMP peptides explained: what GMP grade means, GLP vs GMP, and research grade vs GMP grade
- How to read a peptide COA: every test explained, red flags and how to verify it
- HPLC method validation under ICH Q2(R2) and Q14: a practical guide for peptide purity and assay methods
- What is ICH Q11? Starting materials, control strategy and Q6A/Q6B specifications for peptide drug substances
- ICH Q7 explained: GMP for active pharmaceutical ingredients, chapter by chapter, with peptide APIs in focus
- Linaclotide: what it is, how it works and what studies have found
Lyophilization services: how to choose a contract lyophilization CMO, and what to send them
- Mazdutide: what it is, how it works and what studies have found
- Net peptide content vs HPLC purity: how amino acid analysis and mass balance measure the peptide in the vial
- What is a peptide bond? Formation, structure, hydrolysis and laboratory synthesis
Shipping peptides in the cold chain: packaging, dry-ice rules, receiving checks, excursions and long-term storage
- Peptide counter-ions: TFA vs acetate vs hydrochloride, and why the salt form changes your results
- How do peptides degrade? Degradation pathways, warning signs and stability testing
- Peptide mass spectrometry: how ESI, MALDI, MS/MS and LC-MS confirm a peptide's identity
- Peptide modifications for stability and half-life: lipidation, PEGylation, Aib, cyclisation and fusion
- Peptide purification: preparative HPLC, ion exchange and the yield versus purity trade-off
- Peptide purity testing: how HPLC, mass spectrometry and amino acid analysis work together
- Peptide synthesis: how peptides are made, from the first resin bead to a purified kilogram
How to reconstitute lyophilized peptides in the lab: solvent choice, stock solutions, storage and troubleshooting
- Retatrutide: what it is, how it works and what studies have found
- Retatrutide vs tirzepatide: how the triple and dual agonists compare
- Semaglutide: what it is, how it works and what studies have found
- Sermorelin: what it is, how it works and what studies have found
- Survodutide: what it is, how it works and what studies have found
- TB-500: what it is, how it works and what studies have found
- Teduglutide: what it is, how it works and what studies have found
- Tesamorelin: what it is, how it works and what studies have found
- Tirzepatide: what it is, how it works and what studies have found
What is a lyophilized peptide? Freeze-drying explained, from the three stages to the finished cake
- What is a peptide? Definition, types, functions and how peptides are made
What is WHO-GMP certification? Who issues it, what it covers and how buyers verify it
CDMO vs CMO vs CRDMO: what is the difference, and which one does a pharma buyer need?
Generic semaglutide: EU and US regulatory pathways, and what API makers must show
How to qualify a peptide API supplier: a documentation and audit checklist for EU and US buyers
Lyophilized (lyophilised) peptide stability and storage: how long a peptide API lasts and how to keep it
Peptide API impurities and specifications: thresholds, tests and what regulators expect in 2026
Peptide lyophilization (lyophilisation): a practical guide to freeze-drying peptide APIs
How to read a semaglutide API certificate of analysis (COA)
Semaglutide patent expiry by country: dates, status and what it means for API buyers
Semaglutide vs tirzepatide vs liraglutide: how the three peptide APIs compare
SPPS vs LPPS vs hybrid: how peptide APIs are manufactured, and why the route matters to buyers
What is a peptide API? API vs drug substance explained